Cocrystal Pharma, Inc.: OPKO HEALTH, INC. amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
OPKO Health, Inc. filed an amended Schedule 13D with the SEC (accession 0000944809-26-000003) updating its beneficial ownership stake in Cocrystal Pharma, Inc. The amendment discloses a change to OPKO's previously reported position in the clinical-stage antiviral drug developer. The filing matters because Schedule 13D amendments signal shifts in a major holder's influence over corporate strategy and governance at the smaller company. Investors will watch for the specific share count and percentage change detailed in the filing, and whether further purchases or sales follow.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Cocrystal Pharma, Inc., OPKO Health, Inc.